G01N 2333/7055
Integrin beta1-subunit-containing molecules
Official title: Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
G01N2333/7055 (Integrin beta1-subunit-containing molecules) appears on 42 US grants and 96 published applications in this corpus.
Search patents in G01N- Granted patents
- 42
- Published applications
- 96
- Assignees
- 65
- Inventors
- 197
- Latest grant
- 12 Aug 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 5 |
| 2005 | 0 | 1 |
| 2006 | 1 | 4 |
| 2007 | 1 | 5 |
| 2008 | 3 | 3 |
| 2009 | 1 | 4 |
| 2010 | 4 | 4 |
| 2011 | 1 | 7 |
| 2012 | 1 | 7 |
| 2013 | 2 | 4 |
| 2014 | 5 | 4 |
| 2015 | 2 | 12 |
| 2016 | 5 | 8 |
| 2017 | 4 | 1 |
| 2018 | 4 | 4 |
| 2019 | 3 | 0 |
| 2020 | 0 | 3 |
| 2021 | 1 | 0 |
| 2022 | 2 | 5 |
| 2023 | 0 | 3 |
| 2024 | 0 | 1 |
| 2025 | 2 | 4 |
| 2026 | 0 | 6 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Anti-VLA-4 related assays12 Aug 2025US 12,385,925 B2Biogen MA Inc.
- Anti-beta 1 integrin humanized antibody, and pharmaceutical composition for treating cancer, comprising same3 Jun 2025US 12,319,732 B2SG Medical, Inc.
- Anti-VLA-4 related assays22 Mar 2022US 11,280,793 B2Biogen MA Inc.
- Administration of agents for the treatment of inflammation15 Feb 2022US 11,248,051 B2Biogen MA Inc.
- Anti-integrin β1 antibody compositions and methods of use thereof12 Oct 2021US 11,142,576 B2Oncosynergy, Inc.
- Compositions and methods involving integrin alpha3beta11 Oct 2026US 2026/0297198 A1149 Bio, LLC
- Use of integrin a5b1 as target in screening of drugs for preventing and/or treating bone loss23 Jul 2026US 2026/0207645 A1The Hong Kong Polytechnic University
- Anti-alpha5 integrin antibodies and uses thereof9 Jul 2026US 2026/0193361 A1Pasithea Therapeutics Corp.
- Methods for treating endometrial and ovarian hyperproliferative disorders12 Feb 2026US 2026/0042843 A1Temple Therapeutics, Inc.
- Compositions and methods related to inhibition of adenomas and adenocarcinomas5 Feb 2026US 2026/0034081 A1The Trustees of Columbia University in the City of New York
Most cited
By later US patents
- Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodies55US 8,246,958 B2Elan Pharmaceuticals, Inc. · 2012
- Administration of agents for the treatment of inflammation30US 7,807,167 B2Elan Pharmaceuticals, Inc. · 2010
- Anti-alphavbeta1 integrin inhibitors and methods of use14US 10,214,522 B2The Regents of the University of California · 2019
- Monoclonal antibody capable of binding integrin alpha 10 beta 114US 7,452,677 B2Cartela R&D AB · 2008
- Humanized anti-VLA4 immunoglobulins13US 7,435,802 B2Elan Pharaceuticals, Inc. · 2008